- Home
- VERI vs HURA Comparison
VERI vs HURA Comparison
Compare VERI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERI
- HURA
- Stock Information
- Founded
- VERI 2014
- HURA 2009
- Country
- VERI United States
- HURA United States
- Employees
- VERI N/A
- HURA N/A
- Industry
- VERI EDP Services
- HURA
- Sector
- VERI Technology
- HURA
- Exchange
- VERI Nasdaq
- HURA Nasdaq
- Market Cap
- VERI 145.4M
- HURA 145.6M
- IPO Year
- VERI 2017
- HURA N/A
- Fundamental
- Price
- VERI $2.84
- HURA $2.75
- Analyst Decision
- VERI Strong Buy
- HURA Strong Buy
- Analyst Count
- VERI 3
- HURA 2
- Target Price
- VERI $4.00
- HURA $11.50
- AVG Volume (30 Days)
- VERI 2.7M
- HURA 791.7K
- Earning Date
- VERI 08-07-2025
- HURA 08-14-2025
- Dividend Yield
- VERI N/A
- HURA N/A
- EPS Growth
- VERI N/A
- HURA N/A
- EPS
- VERI N/A
- HURA N/A
- Revenue
- VERI $90,902,000.00
- HURA N/A
- Revenue This Year
- VERI $19.12
- HURA N/A
- Revenue Next Year
- VERI $22.96
- HURA N/A
- P/E Ratio
- VERI N/A
- HURA N/A
- Revenue Growth
- VERI N/A
- HURA N/A
- 52 Week Low
- VERI $1.22
- HURA $1.80
- 52 Week High
- VERI $5.64
- HURA $8.40
- Technical
- Relative Strength Index (RSI)
- VERI 61.71
- HURA 48.78
- Support Level
- VERI $2.27
- HURA $2.77
- Resistance Level
- VERI $3.20
- HURA $3.30
- Average True Range (ATR)
- VERI 0.23
- HURA 0.28
- MACD
- VERI 0.02
- HURA -0.02
- Stochastic Oscillator
- VERI 75.00
- HURA 10.35
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.